Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the Annual Secretarial Compliance Report dated 15th May 2026, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd has filed its Annual Secretarial Compliance Report for the financial year ended 31st March 2026, as per SEBI Regulation 24A. The report, issued by Practicing Company Secretary Ms. Twinkle Agarwal, shows the company largely complied with SEBI regulations. Two non-compliances were noted: (1) failure to maintain proper board composition including not appointing a woman director under Regulation 17(1), with a fine of Rs 5,42,800 imposed but later waived by BSE upon application; and (2) improper constitution of Nomination and Remuneration Committee under Regulation 19(1)/(2), with a fine of Rs 2,17,120 also waived. The company has since appointed two Independent Directors including a woman director w.e.f. 08.10.2025. All other compliance areas including secretarial standards, insider trading norms, related party transactions, and website disclosures were found satisfactory.
The filing shows regulatory issues have been resolved with fines waived. Board composition and committee constitution have been corrected, which is positive for shareholders as it indicates improved corporate governance compliance.